Italian supercar maker Ferrari (NYSE:RACE) said on Tuesday it had signed a deal with Samsung (KS:005930) Display to use its organic light-emitting diode (OLED) display…
Virgin Orbit’s would-be white knight and a $200 million rescue that fell flat
As the fortunes of Richard Branson’s Virgin Orbit were crashing to Earth last month, a little-known investor called Matthew Brown appeared offering a $200 million…
Alibaba’s breakup lifts hopes China’s regulatory winter is thawing
Investors cheered a major revamp of Alibaba (NYSE:BABA) Group as a sign Beijing’s crackdown on the corporate sector was nearing an end, sending shares of the Jack…
U.S. rejects JetBlue, Spirit exemption request, citing lawsuit
The U.S. Transportation Department on Friday denied an exemption request by JetBlue and Spirit to operate under common ownership, citing the Justice Department’s antitrust lawsuit…
Stifel resumes Alphabet coverage at Buy, sees nearly 30% upside potential
Stifel analysts resumed research coverage of Alphabet (NASDAQ:GOOGL) at Buy with a price target of $130 per share. Despite investor concerns about the success of…
Credit Suisse lifeline, First Republic rescue What you need to know
Credit Suisse began a make-or-break weekend after some rivals grew cautious in their dealings with the struggling Swiss lender, and its regulators urged it to…
Rio Tinto appoints directors with mining, renewable energy experience
Rio Tinto (NYSE:RIO) has appointed two non-executive directors, the miner said on Thursday, in response to its chairman’s call for more members with experience in…
Samsung Electronics to invest $230 billion through 2042 in South Korea chipmaking base
South Korean tech giant Samsung Electronics (OTC:SSNLF) expects to invest $230 billion over the next 20 years to develop what the country’s government called the…
Airbus faces steep climb in ‘make or break’ delivery year
Airbus and U.S. rival Boeing (NYSE:BA) were locked in a dead heat for deliveries for the first two months of the year, but the European…
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
The blood thinner Eliquis from Bristol Myers (NYSE:BMY) Squibb, Pfizer (NYSE:PFE)’s breast cancer drug Ibrance and AbbVie (NYSE:ABBV)’s leukemia treatment Imbruvica are likely to be among 10…